secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001193125-24-061288
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno reports Q4 net loss $11.3M; NDA for DCCR in PWS on track for mid-2024
----------------------------------------------------------------------------

- Cash and equivalents $169.7M at Dec 31, 2023, boosted by $129M Oct 2023 offering and $43.1M warrant exercises.
- R&D expenses rose to $8.7M (Q4 2023) vs $3.8M (Q4 2022); full-year $25.2M vs $15.3M.
- Corrected G&A for Q4 2023: $4.1M vs previously reported $4.4M; full-year $13.5M vs $9.8M.
- Positive top-line data from C602 withdrawal: primary endpoint met (p=0.0022); DCCR well-tolerated.
- Leadership additions: Meredith Manning as CCO, Dairine Dempsey VP Europe, Lauren Budesheim VP HR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312524061288/0001193125-24-061288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312524061288/d764812d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-061288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer